CymaBay Therapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • CymaBay Therapeutics's estimated annual revenue is currently $6.8M per year.(i)
  • CymaBay Therapeutics received $Undisclosed in venture funding in January 2018.
  • CymaBay Therapeutics's estimated revenue per employee is $75,933
  • CymaBay Therapeutics's total funding is $366.5M.
  • CymaBay Therapeutics's current valuation is $266.7M. (January 2022)

Employee Data

  • CymaBay Therapeutics has 90 Employees.(i)
  • CymaBay Therapeutics grew their employee count by 50% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH). For additional information about CymaBay visit

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





CymaBay Therapeutics News

2022-04-17 - Zacks: Brokerages Anticipate CymaBay Therapeutics, Inc ...

Equities research analysts predict that CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) will announce earnings per share (EPS) of...

2022-04-17 - Institutional owners may take dramatic actions as CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) recent 13% drop adds to one-year losses

Hence, if weakness in CymaBay Therapeutics' share price continues, institutional investors may feel compelled to sell the stock, which might not...

2022-03-30 - CymaBay Therapeutics Announces Publication of Results ...

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic...

2021-08-02 - CymaBay secures $100M to bankroll phase 3 development of resurrected liver drug Clinical Quality Oversight Forum

A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now has $100 million to bankroll a phase 3 study of the drug. RELATED: CymaBay resurrects seladelpar 8 months after NASH flop In November, the Newark, California-based biopharma presented data showi ...

2021-08-02 - CymaBay Therapeutics : Announces $100 Million Non-Dilutive Financing with Abingworth

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

CymaBay Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-31$UndisclosedUndisclosedLeerink Partners LLCArticle